Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline

Abstract

The Task Force recommends that initial biochemical testing for PPGLs should include measurements of plasma free or urinary fractionated metanephrines. Consideration should be given to preanalytical factors leading to false-positive or false-negative results. All positive results require follow-up. Computed tomography is suggested for initial imaging, but magnetic resonance is a better option in patients with metastatic disease or when radiation exposure must be limited. (123)I-metaiodobenzylguanidine scintigraphy is a useful imaging modality for metastatic PPGLs. We recommend consideration of genetic testing in all patients, with testing by accredited laboratories. Patients with paraganglioma should be tested for SDHx mutations, and those with metastatic disease for SDHB mutations. All patients with functional PPGLs should undergo preoperative blockade to prevent perioperative complications. Preparation should include a high-sodium diet and fluid intake to prevent postoperative hypotension. We recommend minimally invasive adrenalectomy for most pheochromocytomas with open resection for most paragangliomas. Partial adrenalectomy is an option for selected patients. Lifelong follow-up is suggested to detect recurrent or metastatic disease. We suggest personalized management with evaluation and treatment by multidisciplinary teams with appropriate expertise to ensure favorable outcomes.

Keywords

Affiliated Institutions

• Université Paris Cité FR
• Assistance Publique – Hôpitaux de Paris FR
• Mayo Clinic US
• Délégation Paris 5 FR
• San Francisco VA Medical Center US
• Eunice Kennedy Shriver National Institute of Child Health and Human Development US
• Kyoto Medical Center JP
• Hôpital Européen FR
• Radboud University Medical Center NL
• University of California, San Francisco US
• WinnMed US
• Radboud University Nijmegen NL
• Hôpital Européen Georges-Pompidou FR

Related Publications